Danaher Corp
NYSE:DHR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
174.64
250.59
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Danaher Corp
Once upon a time, back in 1984, two brothers, Steven and Mitchell Rales, envisioned a company that would revolutionize the manufacturing sphere, setting the roots for what would become Danaher Corporation. Born from the acquisition of a real estate investment trust, they pivoted to a broader industrial manufacturing approach, aligning themselves with the then unique concept of lean manufacturing and continuous improvement – known as the Danaher Business System (DBS). This philosophy helped them transform Danaher into an assembly of high-performance companies. Over the decades, the corporation honed its focus, shedding non-core assets, and refining its portfolio to center on biotechnology, life sciences, environmental and applied solutions, and diagnostics. Through strategic acquisitions and relentless innovation, Danaher has continued to evolve, constantly reshaping itself to meet the demands of critical sectors.
Today, Danaher's operations are driven by three powerful segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Its Life Sciences segment enables breakthrough discoveries that advance scientific research, healthcare, and more. Meanwhile, the Diagnostics division delivers critical tools that aid clinical laboratories and physicians in patient care, offering blood and infection analysis technologies, among others. Finally, Environmental & Applied Solutions focuses on water quality and product-identification services, crucial for maintaining health and safety standards across industries. By continually investing in innovation and focusing on operational efficiencies through DBS, Danaher not only positions itself as a leader in these sectors—it harnesses market needs into profitable solutions, ensuring its growth and stability in a competitive global market.
Once upon a time, back in 1984, two brothers, Steven and Mitchell Rales, envisioned a company that would revolutionize the manufacturing sphere, setting the roots for what would become Danaher Corporation. Born from the acquisition of a real estate investment trust, they pivoted to a broader industrial manufacturing approach, aligning themselves with the then unique concept of lean manufacturing and continuous improvement – known as the Danaher Business System (DBS). This philosophy helped them transform Danaher into an assembly of high-performance companies. Over the decades, the corporation honed its focus, shedding non-core assets, and refining its portfolio to center on biotechnology, life sciences, environmental and applied solutions, and diagnostics. Through strategic acquisitions and relentless innovation, Danaher has continued to evolve, constantly reshaping itself to meet the demands of critical sectors.
Today, Danaher's operations are driven by three powerful segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Its Life Sciences segment enables breakthrough discoveries that advance scientific research, healthcare, and more. Meanwhile, the Diagnostics division delivers critical tools that aid clinical laboratories and physicians in patient care, offering blood and infection analysis technologies, among others. Finally, Environmental & Applied Solutions focuses on water quality and product-identification services, crucial for maintaining health and safety standards across industries. By continually investing in innovation and focusing on operational efficiencies through DBS, Danaher not only positions itself as a leader in these sectors—it harnesses market needs into profitable solutions, ensuring its growth and stability in a competitive global market.
Revenue Beat: Danaher exceeded expectations in Q3 2025, with revenue, earnings, and cash flow all coming in ahead of guidance.
Strong Bioprocessing: Bioprocessing core revenue grew high single digits, driven by robust demand for consumables, especially in monoclonal antibodies.
Diagnostics Outperformance: Diagnostics core revenue rose 3.5%, with notable strength in Beckman Coulter (outside China) and a better-than-expected respiratory season at Cepheid.
Margin Expansion: Adjusted operating profit margin increased by 40 basis points year-over-year, attributed to higher volume and disciplined cost control.
Share Buybacks & Authorization: Approximately $2 billion was spent to repurchase 10 million shares, and a new buyback program for up to 35 million shares was approved.
2025 & 2026 Guidance: Full-year 2025 EPS guidance was maintained at $7.70 to $7.80. For 2026, management expects 3% to 6% core revenue growth, more than 100 basis points of margin expansion, and high single-digit EPS growth.
Productivity Investments: $175 million in cost actions for 2025 are expected to yield $250 million in savings for 2026, giving a $0.30 EPS tailwind.
China Headwinds: China remains a challenging market, especially in Diagnostics due to policy and reimbursement changes, but headwinds are expected to diminish in 2026.
Management
Steven M. Rales is a prominent American businessman and one of the co-founders of Danaher Corporation, a globally diversified conglomerate. Born in 1951, Rales initially pursued a career in law before joining his family's real estate business. Alongside his brother, Mitchell Rales, he founded Danaher Corporation in 1984, named after a tributary of the South Fork Potomac River. Under his leadership, Danaher employed the "Danaher Business System," a set of principles modeled after the Japanese manufacturing concept of kaizen, focusing on continuous improvement and operational efficiency. This approach facilitated the company's rapid growth and expansion into various sectors such as environmental, life sciences, diagnostics, and dental industries. Steven Rales is known for his strategic vision and ability to steer the company towards acquisitions that complement and enhance its technology and product offerings. His role at Danaher helped transform it from a manufacturing company into a leading global science and technology innovator. In addition to his work with Danaher, Rales is engaged in other ventures and philanthropic efforts, often focusing on cultural and educational pursuits. He is also known for his involvement in the film industry through his production company, Indian Paintbrush, which has supported several critically acclaimed films.
Under his leadership, Danaher employed the "Danaher Business System," a set of principles modeled after the Japanese manufacturing concept of kaizen, focusing on continuous improvement and operational efficiency. This approach facilitated the company's rapid growth and expansion into various sectors such as environmental, life sciences, diagnostics, and dental industries.
Steven Rales is known for his strategic vision and ability to steer the company towards acquisitions that complement and enhance its technology and product offerings. His role at Danaher helped transform it from a manufacturing company into a leading global science and technology innovator.
In addition to his work with Danaher, Rales is engaged in other ventures and philanthropic efforts, often focusing on cultural and educational pursuits. He is also known for his involvement in the film industry through his production company, Indian Paintbrush, which has supported several critically acclaimed films.
Rainer M. Blair is the President and Chief Executive Officer of Danaher Corporation, a global science and technology company. He was appointed CEO of Danaher in September 2020. Before becoming the CEO, Blair joined Danaher in 2010 and held several leadership positions within the company, including Executive Vice President of Danaher's Life Sciences segment. Under Blair's leadership, the Life Sciences segment expanded significantly through strategic acquisitions and organic growth, strengthening Danaher's position in the life sciences and diagnostics markets. With a career spanning more than three decades, Blair has extensive experience in managing and growing global businesses, focusing on innovation, operational excellence, and transformative growth. Before joining Danaher, Blair held various leadership roles at companies like MAPEI Americas, a construction chemicals company, and BASF, where he developed and executed growth strategies across different global markets. Blair is known for his commitment to fostering a culture of continuous improvement and innovation within Danaher, ensuring the company remains at the forefront of scientific and technological advances. His leadership style emphasizes collaboration, transparency, and a customer-centric approach, aligning with Danaher's reputation for successful business practices.
Under Blair's leadership, the Life Sciences segment expanded significantly through strategic acquisitions and organic growth, strengthening Danaher's position in the life sciences and diagnostics markets. With a career spanning more than three decades, Blair has extensive experience in managing and growing global businesses, focusing on innovation, operational excellence, and transformative growth.
Before joining Danaher, Blair held various leadership roles at companies like MAPEI Americas, a construction chemicals company, and BASF, where he developed and executed growth strategies across different global markets.
Blair is known for his commitment to fostering a culture of continuous improvement and innovation within Danaher, ensuring the company remains at the forefront of scientific and technological advances. His leadership style emphasizes collaboration, transparency, and a customer-centric approach, aligning with Danaher's reputation for successful business practices.
Mitchell P. Rales is an influential American businessman known for his role as a co-founder of Danaher Corporation, a globally diversified conglomerate. He was born on November 11, 1956, and raised in Bethesda, Maryland. Rales graduated from Walt Whitman High School and later attended Miami University in Ohio. In 1984, along with his brother Steven M. Rales, Mitchell co-founded Danaher Corporation, named after the Danaher Creek in Montana. Under their leadership, Danaher became a leading science and technology innovator, focusing on sectors such as environmental and applied solutions, life sciences, diagnostics, and dental. Mitchell Rales has been pivotal in shaping Danaher's growth strategy, particularly through strategic acquisitions and the implementation of the Danaher Business System, which emphasizes lean manufacturing and continuous improvement. Beyond his work with Danaher, Rales is known for his philanthropy and interest in the arts. He played a key role in establishing Glenstone, a museum in Potomac, Maryland, that combines art, architecture, and landscape, showcasing contemporary art from Rales's personal collection. Rales also serves on various boards and engages in various philanthropic efforts. His leadership and strategic vision have been instrumental in Danaher's transformation into a top-performing, innovative industrial company.
In 1984, along with his brother Steven M. Rales, Mitchell co-founded Danaher Corporation, named after the Danaher Creek in Montana. Under their leadership, Danaher became a leading science and technology innovator, focusing on sectors such as environmental and applied solutions, life sciences, diagnostics, and dental.
Mitchell Rales has been pivotal in shaping Danaher's growth strategy, particularly through strategic acquisitions and the implementation of the Danaher Business System, which emphasizes lean manufacturing and continuous improvement.
Beyond his work with Danaher, Rales is known for his philanthropy and interest in the arts. He played a key role in establishing Glenstone, a museum in Potomac, Maryland, that combines art, architecture, and landscape, showcasing contemporary art from Rales's personal collection.
Rales also serves on various boards and engages in various philanthropic efforts. His leadership and strategic vision have been instrumental in Danaher's transformation into a top-performing, innovative industrial company.
Matthew R. McGrew is a distinguished executive known for his contributions to Danaher Corporation, a globally recognized conglomerate focused on the design, manufacture, and marketing of industrial, healthcare, and consumer products. McGrew served as the Chief Financial Officer (CFO) of Danaher Corporation, where he was responsible for overseeing the company's financial operations, including accounting, financial planning and analysis, tax, investor relations, and internal audit functions. McGrew joined Danaher in 2004 and held various finance roles with increasing responsibility. Before becoming CFO, he served as Vice President of Finance for Danaher's Diagnostics and Dental Platforms. Throughout his tenure, McGrew played a vital role in the company's strategic acquisitions and growth initiatives, helping to drive significant financial performance and shareholder value. His leadership and expertise in financial management have been instrumental in Danaher's evolution as a leading science and technology innovator. McGrew's career is marked by his analytical skills, strategic acumen, and his ability to navigate complex financial landscapes, all of which have been key to his success at Danaher.
McGrew joined Danaher in 2004 and held various finance roles with increasing responsibility. Before becoming CFO, he served as Vice President of Finance for Danaher's Diagnostics and Dental Platforms. Throughout his tenure, McGrew played a vital role in the company's strategic acquisitions and growth initiatives, helping to drive significant financial performance and shareholder value.
His leadership and expertise in financial management have been instrumental in Danaher's evolution as a leading science and technology innovator. McGrew's career is marked by his analytical skills, strategic acumen, and his ability to navigate complex financial landscapes, all of which have been key to his success at Danaher.
Dr. Jose-Carlos Gutierrez-Ramos is a distinguished scientist and executive with a notable career in the biotechnology and pharmaceutical industries. He has held leadership roles across several major companies, contributing to advancements in life sciences and medicine. At Danaher Corporation, Dr. Gutierrez-Ramos serves as the Senior Vice President and Chief Scientific Officer. In this role, he oversees the scientific strategies of the corporation's diverse life sciences and diagnostics platforms. His work supports Danaher's innovation initiatives, driving scientific research that aligns with the company’s goals of improving healthcare solutions. Before joining Danaher, he held several key positions in the industry. Notably, he was the CEO of Synlogic, a biotechnology company focused on developing synthetic biology-driven therapeutics. Prior to that, he served as the Global Head of Drug Discovery at AbbVie, where he was responsible for overseeing research and development efforts. Dr. Gutierrez-Ramos has also been part of Biogen Idec, Pfizer, and several other major firms. Throughout his career, he has been known for fostering innovation through collaborative scientific environments, focusing on cutting-edge drug discovery and development, and strategic research initiatives. With a Ph.D. in Immunochemistry from the Universidad Complutense in Spain, Dr. Gutierrez-Ramos has a strong foundation in immunology and molecular biology, which he has applied throughout his career to advance scientific knowledge and patient outcomes. His work has not only contributed to the companies he has worked for but also to the scientific community at large through numerous publications and leadership in various research initiatives.
At Danaher Corporation, Dr. Gutierrez-Ramos serves as the Senior Vice President and Chief Scientific Officer. In this role, he oversees the scientific strategies of the corporation's diverse life sciences and diagnostics platforms. His work supports Danaher's innovation initiatives, driving scientific research that aligns with the company’s goals of improving healthcare solutions.
Before joining Danaher, he held several key positions in the industry. Notably, he was the CEO of Synlogic, a biotechnology company focused on developing synthetic biology-driven therapeutics. Prior to that, he served as the Global Head of Drug Discovery at AbbVie, where he was responsible for overseeing research and development efforts.
Dr. Gutierrez-Ramos has also been part of Biogen Idec, Pfizer, and several other major firms. Throughout his career, he has been known for fostering innovation through collaborative scientific environments, focusing on cutting-edge drug discovery and development, and strategic research initiatives.
With a Ph.D. in Immunochemistry from the Universidad Complutense in Spain, Dr. Gutierrez-Ramos has a strong foundation in immunology and molecular biology, which he has applied throughout his career to advance scientific knowledge and patient outcomes. His work has not only contributed to the companies he has worked for but also to the scientific community at large through numerous publications and leadership in various research initiatives.
Mr. Christopher M. Bouda serves as the Senior Vice President and Corporate Controller at Danaher Corporation. In his role, he is responsible for overseeing the company's accounting and financial reporting functions. Mr. Bouda has played a key part in shaping and directing the finance strategies at Danaher, contributing to both its growth and operational excellence. His extensive experience in finance and accounting has been instrumental in enhancing the company's financial performance and integrity across its diverse business segments. Throughout his tenure at Danaher, he has been recognized for his leadership and expertise in ensuring compliance and fostering financial best practices within the organization.
John Bedford is not a widely recognized executive in the public domain related to Danaher Corporation. It's possible that he may hold a position that hasn't been prominently documented in publicly available resources or that he may work in a different capacity that isn't broadly covered in the media. If you have any additional context or details about his role, that might help in providing more specific information. Otherwise, this might be an instance where information about the individual isn't readily accessible.
Brian W. Ellis, J.D. serves as Senior Vice President and General Counsel for Danaher Corporation, a global science and technology innovator. In this role, he is responsible for overseeing Danaher's legal functions, including corporate governance, compliance, regulatory affairs, and litigation. Before joining Danaher, Ellis gained extensive legal and corporate experience at The Kraft Heinz Company, where he held the position of Senior Vice President, General Counsel, and Corporate Secretary. His career also includes roles at firms such as Jones Day, where he focused on complex commercial litigation and regulatory compliance. Ellis holds a Juris Doctor degree, equipping him with a solid foundation in law, which he has effectively applied in his various leadership roles in corporate settings. His expertise aids Danaher in navigating the legal landscapes across different jurisdictions and in strategic decision-making processes.
Before joining Danaher, Ellis gained extensive legal and corporate experience at The Kraft Heinz Company, where he held the position of Senior Vice President, General Counsel, and Corporate Secretary. His career also includes roles at firms such as Jones Day, where he focused on complex commercial litigation and regulatory compliance.
Ellis holds a Juris Doctor degree, equipping him with a solid foundation in law, which he has effectively applied in his various leadership roles in corporate settings. His expertise aids Danaher in navigating the legal landscapes across different jurisdictions and in strategic decision-making processes.
Daniel A. Raskas, J.D., is a notable executive at Danaher Corporation, a globally recognized science and technology innovator. He serves as the Senior Vice President of Corporate Development, a role that places him at the forefront of the company’s strategic growth initiatives, including mergers and acquisitions, partnerships, and other corporate development activities. Mr. Raskas joined Danaher in 2004 and has been instrumental in driving significant transactions that have helped shape the company’s portfolio and enhance its market leadership across various sectors, including life sciences, diagnostics, environmental, and applied solutions. His expertise in corporate development is backed by his comprehensive experience in law and business management. Before his tenure at Danaher, Daniel Raskas worked in investment banking, where he gained valuable insights into corporate finance and strategy, further honing his skills in structuring and negotiating complex business deals. He holds a Juris Doctor (J.D.) degree, which underpins his analytical and strategic approach to corporate governance and operational excellence. Raskas's contributions are critical to Danaher's ability to innovate and deliver value to customers and shareholders, maintaining its position as a leader in providing scientific and technological solutions worldwide.
Mr. Raskas joined Danaher in 2004 and has been instrumental in driving significant transactions that have helped shape the company’s portfolio and enhance its market leadership across various sectors, including life sciences, diagnostics, environmental, and applied solutions. His expertise in corporate development is backed by his comprehensive experience in law and business management.
Before his tenure at Danaher, Daniel Raskas worked in investment banking, where he gained valuable insights into corporate finance and strategy, further honing his skills in structuring and negotiating complex business deals. He holds a Juris Doctor (J.D.) degree, which underpins his analytical and strategic approach to corporate governance and operational excellence.
Raskas's contributions are critical to Danaher's ability to innovate and deliver value to customers and shareholders, maintaining its position as a leader in providing scientific and technological solutions worldwide.
